Evidence map›Paper›PMID 38843794›Full record

ArticlePlanta medica2024

Increased Glycolytic Activity Is Part of Impeded M1(LPS) Macrophage Polarization in the Presence of Urolithin A.

Sheyda Bahiraii, Barbara Braunböck-Müller, Elke H Heiss

Abstract read
In one paragraph

Article in Planta medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sheyda BahiraiiDepartment of Pharmaceutical Sciences/Pharmacognosy, University of Vienna, Vienna, Austria.
Barbara Braunböck-MüllerDepartment of Pharmaceutical Sciences/Pharmacognosy, University of Vienna, Vienna, Austria.
Elke H HeissDepartment of Pharmaceutical Sciences/Pharmacognosy, University of Vienna, Vienna, Austria.

Funding

Austrian Science Fund P32600Austrian Science Fund FWF P 32600
6 · The paper itself

Abstract

Urolithin A is a gut metabolite of ellagitannins and reported to confer health benefits, e.g., by increased clearance of damaged mitochondria by macroautophagy or curbed inflammation. One targeted cell type are macrophages, which are plastic and able to adopt pro- or anti-inflammatory polarization states, usually assigned as M1 and M2 macrophages, respectively. This flexibility is tightly coupled to characteristic shifts in metabolism, such as increased glycolysis in M1 macrophages, and protein expression upon appropriate stimulation. This study aimed at investigating whether the anti-inflammatory properties of U: rolithin A may be driven by metabolic alterations in cultivated murine M1(lipopolysaccharide) macrophages. Expression and extracellular flux analyses showed that urolithin A led to reduced

Indexed as

CoumarinsGlycolysisLipopolysaccharidesMacrophagesAnimalsAnti-Inflammatory AgentsInterleukin-1betaInterleukin-6MiceNitric Oxide Synthase Type II3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAnti-Inflammatory AgentsCoumarinsInterleukin-1betaInterleukin-6LipopolysaccharidesNitric Oxide Synthase Type II

Identifiers

PMID38843794
PMCPMC11156499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.